reSee.it - Related Video Feed

Brigham Buhler shares his journey from being a drug representative to working in medical devices and eventually becoming an entrepreneur in healthcare. He highlights the flaws in the pharmaceutical and medical device industries, noting that many FDA-approved drugs and devices lack adequate safety studies. He emphasizes that 30% of drugs approved by the FDA face recalls or label changes, and 90% of medical devices used in surgeries have never undergone human safety studies. Buhler discusses the corruption within the healthcare system, particularly how insurance companies and pharmacy benefit managers profit from chronic diseases. He argues that the system is designed to monetize illness rather than promote wellness, leading to unnecessary surgeries and over-prescription of medications. He stresses the importance of patients advocating for themselves by educating themselves and seeking multiple opinions before undergoing procedures. He introduces his company, Wayt to Well, which focuses on preventative care and personalized health solutions, utilizing advanced diagnostics like DEXA scans and VO2 max testing. Buhler advocates for a shift towards proactive health management, emphasizing the need for individuals to take control of their health outside the traditional insurance model. He warns against blind trust in healthcare authorities and encourages questioning the motives behind medical recommendations. Ultimately, he believes that empowering individuals with knowledge and tools can lead to better health outcomes and a more effective healthcare system.

In this podcast episode, Dhru Purohit discusses the detrimental impact of big pharmaceutical companies on the American healthcare system with Dr. John Abramson, a family physician and expert litigator. Dr. Abramson argues that the primary goal of big pharma is profit maximization rather than improving public health. He emphasizes that while pharmaceutical companies do produce essential medications, their influence often leads to misinformation and data manipulation in clinical trials, compromising the integrity of published research. Dr. Abramson highlights that peer-reviewed journals do not have access to complete clinical trial data, which undermines the trust doctors place in published studies. He cites the example of Vioxx, an anti-inflammatory drug that caused significant cardiovascular risks, yet its dangers were downplayed in medical literature. This lack of transparency extends to clinical practice guidelines, which are often based on incomplete data. The conversation also touches on the relationship between pharmaceutical companies and doctors, noting that many physicians are unaware of the extent to which commercial interests shape the information they receive. Dr. Abramson stresses the need for a more balanced approach to healthcare that includes addressing social determinants of health, rather than solely focusing on new drug development. He proposes that three constituencies—doctors, businesses purchasing healthcare, and the American public—must unite to demand transparency and accountability from pharmaceutical companies. Dr. Abramson advocates for reforms such as health technology assessments, cost-effectiveness research, and stricter penalties for corporate malfeasance to protect public health. The episode concludes with a call for open dialogue and collaboration across political lines to improve healthcare outcomes, emphasizing the importance of public education and coalition-building to challenge the current system. Dr. Abramson's book, "The Sickening: How Big Pharma Broke American Healthcare and How We Can Repair It," serves as a resource for understanding these issues and advocating for change.

The episode centers on the escalating outcry over healthcare’s structural failures, catalyzed by the case of Luigi Mangione and the broader critique of United Healthcare’s leadership. Brigham Feler, founder of Ways to Well, argues that the crisis is less about individual villains and more about a system that monetizes illness through opaque pricing, aggressive insurance practices, and monopolistic control by Pharmacy Benefit Managers and big insurers. He details how long approval times for surgeries like spinal procedures forces patients toward opioids, creates dependency, and exposes chronic pain patients to a brutal, dehumanizing process that prioritizes profitability over healing. Feler connects the patient experience to high-level incentives and incentives in the pharmaceutical and insurance sectors. He accuses United Healthcare of deploying AI denial programs that rejected up to 90% of claims, notes a DOJ probe into monopoly practices, and highlights how stock-driven decisions can deprioritize patient welfare. The conversation expands into the mechanics of price manipulation— rebates, middlemen, spread pricing, and the influence of PBMs owned by the major insurers—arguing that these schemes drive up costs for individuals, employers, and taxpayers while masking profits behind complex, opaque billing. The guests discuss real-world consequences: delayed care, debt, and bankruptcy amid a system that discourages preventative measures and suppresses alternative, lower-cost care models. The dialogue culminates in a practical call to action: regain sovereignty over health through cash-pay clinics and proactive, predictive care that looks “under the hood” at more than a handful of biomarkers. The hosts advocate for a shift away from sick-care to prevention, critique the incentives that discourage comprehensive testing, and present Ways to Well as a model aiming to democratize access to thorough blood work, personalized nutrition, and AI-assisted health planning. The episode closes on an urgent reminder that meaningful reform will require individuals seeking better care, as well as broader changes to how drugs, doctors, and insurers interact in a system widely perceived as prioritizing profits over people.

Chris Williamson discusses the primary cause of bankruptcy in America, which is healthcare costs, with Brigham Buhler. Buhler attributes the broken healthcare system to various factors, including diet, lifestyle, and the corporate capture of healthcare institutions. He highlights the alarming increase in approved food ingredients in the U.S. compared to Europe and criticizes the insurance model that prioritizes profits over patient care. Buhler explains that the healthcare system is designed to monetize chronic diseases, with insurance companies profiting significantly more than pharmaceutical companies. He emphasizes the lack of awareness among the public regarding Pharmacy Benefit Managers (PBMs) and their detrimental impact on healthcare access. He notes that the average American is often unaware of how insurance companies control treatment options and access to care. The conversation touches on the opioid crisis, where Buhler points out that while opioids are harder to access now, many individuals have turned to dangerous alternatives due to restrictions. He discusses the failures of the FDA and the collusion between regulatory bodies and pharmaceutical companies, leading to a lack of accountability and oversight. Buhler advocates for a shift towards preventative care and proactive health management, emphasizing the importance of metabolic health. He suggests that the future of healthcare lies in technology, AI, and personalized medicine, which can provide real-time feedback and encourage healthier lifestyle choices. He encourages individuals to take control of their health by seeking cash-pay clinics and comprehensive blood work, rather than relying solely on insurance-based systems. The conversation concludes with a focus on the need for systemic change in healthcare, driven by transparency and accountability, to improve health outcomes for Americans.

Tucker Carlson discusses the recent murder of a health insurance CEO in New York, highlighting that 41% of younger people express support for the act, which reflects a deeper hostility towards insurance companies. Brigham Buhler emphasizes that while violence is never justified, the insurance industry contributes to a chronic disease crisis in America by prioritizing profit over patient care. He argues that insurance companies profit from delaying care and procedures, which exacerbates health issues. Buhler explains the evolution of health insurance, noting that it began as a means to provide consistent care but shifted to a profit-driven model with the rise of HMOs in the 1980s. He contrasts the personalized care of pre-HMO days with the current system, where doctors spend an average of just six minutes with patients due to insurance constraints. The conversation shifts to pharmacy benefit managers (PBMs), which Buhler describes as unnecessary middlemen that inflate drug prices through kickbacks. He cites examples of how PBMs manipulate drug costs, leading to higher expenses for patients and employers. Buhler reveals that a significant portion of health insurance profits comes from Medicare and Medicaid, with insurance companies negotiating prices based on inflated average wholesale prices. Buhler stresses the need for a shift towards preventative care, arguing that the current system fails to address the root causes of chronic diseases, which are often lifestyle-related. He highlights the importance of comprehensive blood work and proactive health assessments to prevent diseases before they develop. The discussion touches on the opioid crisis, with Buhler sharing personal experiences of how insurance companies incentivize the prescription of addictive medications over non-addictive alternatives. He argues that the healthcare system is designed to profit from chronic illness rather than promote wellness. Buhler expresses hope for reform, particularly with potential changes under Donald Trump and Bobby Kennedy, emphasizing the need for a healthcare system that prioritizes patient outcomes over profits. He advocates for cash-pay clinics that focus on preventative care, allowing patients to take control of their health without the interference of insurance companies.

In episode 351, Patrick Bet-David interviews Dr. John Abramson, an American physician and author of "Overdosed America" and "Sickening." Abramson discusses his extensive background in medicine, including his work at Harvard Medical School and his experiences with the pharmaceutical industry. He highlights the withdrawal of Vioxx shortly after his book's release, which had caused significant harm despite being no more effective than cheaper alternatives. The conversation shifts to Abramson's views on vaccines, particularly regarding the COVID-19 vaccine rollout. He expresses concerns about the lack of randomized control trials for boosters and the reliance on observational data, which can be misleading. He recounts a personal health crisis that led him to question the recommendations made by healthcare professionals, emphasizing the inadequacies in the peer review process and the influence of pharmaceutical companies on medical guidelines. Abramson critiques the financial model of medical journals, which often prioritize profits from pharmaceutical advertising over unbiased research. He argues that the pharmaceutical industry has a significant grip on healthcare, leading to a misallocation of resources and a focus on profit rather than patient health. He points out that the FDA and CMS have conflicting roles, complicating the evaluation of drug efficacy and safety. The discussion also touches on the political landscape, with Abramson noting that both parties are complicit in accepting pharmaceutical funding, which undermines public health interests. He advocates for a shift in focus towards lifestyle interventions and preventive care, rather than solely relying on medications. Abramson concludes by stressing the need for transparency and accountability in the pharmaceutical industry to improve American healthcare outcomes.

Modern healthcare is fundamentally flawed due to economic incentives that profit from prolonged illness rather than promoting health. Insurance companies, under the Affordable Care Act, are incentivized to raise premiums, which leads to higher costs and more sickness. Pharmaceutical companies focus on chronic disease management, as 95% of their sales come from treatments for conditions like heart disease and diabetes, which require ongoing medication rather than cures. This creates a cycle where sick patients are more profitable. Childhood obesity and chronic diseases are rising, with 50% of teens overweight or obese. The pharmaceutical industry profits from this trend, as a healthy child is not a profitable patient. The healthcare system is structured to prioritize interventions and treatments over preventative measures. Hospitals, as the largest employers, are incentivized to fill beds and perform procedures, often leading to unnecessary surgeries and prescriptions. The healthcare system's focus on treating symptoms rather than root causes is evident in the rise of medications like statins and antidepressants, which are prescribed without addressing lifestyle factors. The American Academy of Pediatrics has recently recommended aggressive interventions for overweight children, influenced by pharmaceutical funding. Environmental factors, including diet and toxins, contribute significantly to chronic health issues. The prevalence of ultra-processed foods, heavily subsidized and marketed, exacerbates these problems. The U.S. food system is designed to promote unhealthy eating habits, with government programs like SNAP allowing the purchase of sugary drinks. The conversation around health must shift from treating diseases to promoting overall wellness. This includes recognizing the interconnectedness of various health conditions and addressing metabolic dysfunction as a root cause. The healthcare system needs to be reoriented to prioritize preventative care and holistic health solutions. The current trajectory of healthcare spending is unsustainable, with chronic diseases projected to bankrupt the system. There is a need for bipartisan action to reform healthcare policies, focusing on clean food and water, and addressing the systemic issues that lead to poor health outcomes. The conversation must include a reevaluation of how healthcare is funded and the role of pharmaceutical companies in shaping health guidelines.

Marty Makary discusses significant blind spots in modern medicine, emphasizing that centralized decision-making leads to poor health outcomes. He highlights the alarming trend of the most medicated generation in history and suggests alternative approaches, such as treating diabetes with cooking classes instead of insulin. Makary advocates for a movement within medicine that focuses on food as medicine and the role of inflammation in diseases, while criticizing the NIH and pharmaceutical companies for funding outdated practices. He notes that many physicians lack awareness of the diet-disease connection due to a flawed educational system that prioritizes rote memorization over holistic understanding. Makary critiques the low-fat diet dogma, revealing that major studies disproved its effectiveness in preventing heart disease. He also addresses the consequences of over-prescribing antibiotics, linking them to obesity and chronic diseases in children. The microbiome emerges as a crucial area of research, with studies indicating its impact on health, including learning disabilities and obesity. Makary calls for a reevaluation of medical practices, such as the unnecessary rise in double mastectomies and the overuse of C-sections, advocating for evidence-based approaches. He expresses optimism about the future of medicine, driven by a new generation of doctors eager to challenge the status quo and prioritize patient-centered care. Makary's book, "Blind Spots," aims to educate the public on these critical issues and encourage a shift towards a more sensible healthcare system that values humility, curiosity, and interdisciplinary research.

The conversation features John Abramson, a Harvard Medical School faculty member and author of "Sickening," discussing the detrimental impact of big pharma on American healthcare. Abramson highlights that the pharmaceutical industry prioritizes profit over patient health, leading to a misrepresentation of medical knowledge. He emphasizes the need for "guard rails" to maintain the integrity of healthcare, comparing it to a basketball game without referees, where players are incentivized to win at any cost. Abramson critiques the relationship between pharmaceutical companies and regulatory bodies like the FDA, noting that drug companies often violate laws without facing significant consequences. He cites the case of Pfizer, which was found guilty of fraud and racketeering, as indicative of systemic issues within the industry. He argues that the culture within big pharma normalizes unethical behavior, as employees become desensitized to the consequences of prioritizing shareholder profits. The discussion also touches on the influence of advertising in healthcare, with Abramson asserting that aggressive marketing does not add societal value and often misleads both doctors and patients. He points out that the majority of advertising dollars are spent on promoting drugs to physicians rather than directly to consumers, which shapes medical practice and knowledge. Abramson advocates for a shift in focus from pharmaceutical solutions to preventive measures, such as lifestyle changes, which he believes are often overlooked. He stresses the importance of transparency in clinical trials and calls for independent analysis of drug efficacy compared to lifestyle interventions. The conversation concludes with Abramson reflecting on the moral dilemmas faced by physicians in balancing patient care with the realities of a profit-driven healthcare system. He encourages future medical professionals to enter the field with a commitment to integrity and patient welfare, despite the challenges posed by the current system.

The episode features Jillian Michaels and Brigham Buhler discussing a healthcare system they view as corrupted by powerful entities in pharma and insurance. Buhler recounts his arc from a drug rep to founder of Ways to Well and Revive, detailing how Big Pharma and Big Insurance operate as a cartel that denies, delays, and obstructs patient care to protect profits. He argues that patients are frequently steered away from comprehensive, preventive health strategies toward expensive, disease-driven interventions, highlighting the tension between access to care and the realities of a business-first system. The conversation centers on how misaligned incentives drive up costs while undermining outcomes, from bloated drug prices to opaque rebate structures managed by pharmacy benefit managers (PBMs). They delve into compounding pharmacies as a double-edged sword: essential for affordable, personalized medications and often caricatured by critics, yet targeted by litigation from big manufacturers. Buhler explains the rigorous safety standards some compounding shops uphold, including sterile compounding and third-party validations, while noting the broader problem of 510(k) loopholes and insufficient human trials for many medical devices. The pair also scrutinize GLP-1s and the broader trend of overprescribing, arguing that root causes—nutrition, diet, lifestyle—are underexploited levers for health but underfunded by a system geared toward pharmacologic fixes and chronic revenue. They discuss the cost barriers to advanced diagnostics and preventive testing, pharmacogenetic testing, and the role of comprehensive panels in shaping personalized care. Buhler envisions a future where AI-driven monitoring, predictive testing, and cash-pay clinics like Ways to Well empower individuals to take sovereignty over their health, reduce dependence on insurers, and extend healthspan rather than merely chasing disease management. The dialogue also touches RFK, Casey Means, Callie, and a broader movement advocating diet, prevention, and autonomy, urging listeners to invest in proactive health strategies and to scrutinize the incentives shaping modern medicine. The episode closes with a practical note on affordability, stressing that deeper health insights need not be prohibitively expensive and that a comprehensive baseline can be attained for a few hundred dollars yearly. topics Big Pharma, Big Insurance, healthcare cartels, denials and delays, compounding pharmacies, 510k loopholes, FDA oversight, GLP-1s, preventive medicine, nutrition and lifestyle, predictive medicine, AI in healthcare, Ways to Well, Wastewell, pharmacogenetics, healthspan, RFK, Casey Means, Callie otherTopics Bayer and historical drug testing, opioid crisis, Sackler family history, insulin pricing and PBMs, shadow bans in media, the role of regulation in innovation, privacy concerns with AI health monitoring booksMentioned Bottle of Lies